Correlations of serum syndecan-4 levels on admission with clinical parameters.

<p>Correlations of serum syndecan-4 levels on admission with clinical parameters.</p

Univariate analysis of survival prediction.

<p>Univariate analysis.</p

Clinical characteristics of healthy volunteers, patients with AE-IIP, and patients with SD-IIP.

<p>Clinical characteristics of healthy volunteers, patients with AE-IIP, and patients with SD-IIP.</p

Comparison of serum syndecan-4 levels in healthy volunteers and in patients with SD-IIP and AE-IIP.

<p>Serum syndecan-4 levels were significantly higher in the SD-IIP group than in the HV and AE-IIP groups. Serum syndecan-4 levels did not differ between the HV and AE-IIP groups. HV: healthy volunteer group, SD-IIP: patient group with stable idiopathic interstitial pneumonia, AE-IIP: patient group with acute exacerbation of idiopathic interstitial pneumonia. ANOVA with Tukey HSD was used for statistical analysis. *: p < 0.05 vs HV. †: p < 0.001 vs AE-IIP. Data are expressed as means ± the standard error of the mean (SEM).</p

Kaplan Meier curves of the survival of patients with acute exacerbation of idiopathic interstitial pneumonia who were stratified according to median baseline serum syndecan-4 level.

<p>Baseline serum syndecan-4 levels measurements were obtainable for 34 of the 56 AE-IIP patients. The survival rate was significantly better for patients with low baseline serum syndecan-4 levels than with high baseline serum syndecan-4 levels. (Low baseline serum syndecan-4 group, < 12.8 ng/ml; High baseline serum syndecan-4 group, ≥ 12.8 ng/ml.) A log-rank test was used for statistical analysis.</p

Comparison of the clinical characteristics of survivors and non-survivors of AE-IIP.

<p>Comparison of the clinical characteristics of survivors and non-survivors of AE-IIP.</p

Clinical characteristics of idiopathic interstitial pneumonia patients with high and low baseline serum syndecan-4 levels.

<p>Clinical characteristics of idiopathic interstitial pneumonia patients with high and low baseline serum syndecan-4 levels.</p

Multivariate analysis of survival prediction.

<p>Multivariate analysis.</p

Additional file 1. of A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

CONSORT 2010 checklist of information to include when reporting a randomised trial

Additional file 2: of The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial

SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*. (DOC 121 kb